Pomalidomide for Epistaxis in Hereditary Hemorrhagic Telangiectasia
Pomalidomide for Epistaxis in Hereditary Hemorrhagic Telangiectasia
About this item
Full title
Author / Creator
Al-Samkari, Hanny , Kasthuri, Raj S. , Iyer, Vivek N. , Pishko, Allyson M. , Decker, Jake E. , Weiss, Clifford R. , Whitehead, Kevin J. , Conrad, Miles B. , Zumberg, Marc S. , Zhou, Jenny Y. , Parambil, Joseph , Marsh, Derek , Clancy, Marianne , Bradley, Lauren , Wisniewski, Lisa , Carper, Benjamin A. , Thomas, Sonia M. and McCrae, Keith R.
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
Hereditary hemorrhagic telangiectasia (HHT) is characterized by extensive telangiectasias and arteriovenous malformations. The primary clinical manifestation is epistaxis that results in iron-deficiency anemia and reduced health-related quality of life.
We conducted a randomized, placebo-controlled trial to evaluate the safety and efficacy of po...
Alternative Titles
Full title
Pomalidomide for Epistaxis in Hereditary Hemorrhagic Telangiectasia
Authors, Artists and Contributors
Author / Creator
Kasthuri, Raj S.
Iyer, Vivek N.
Pishko, Allyson M.
Decker, Jake E.
Weiss, Clifford R.
Whitehead, Kevin J.
Conrad, Miles B.
Zumberg, Marc S.
Zhou, Jenny Y.
Parambil, Joseph
Marsh, Derek
Clancy, Marianne
Bradley, Lauren
Wisniewski, Lisa
Carper, Benjamin A.
Thomas, Sonia M.
McCrae, Keith R.
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11412318
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11412318
Other Identifiers
ISSN
0028-4793,1533-4406
E-ISSN
1533-4406
DOI
10.1056/NEJMoa2312749
